A Phase 1B Dose-Escalation Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Patients With Stage 4 Non-Squamous Cell Lung Cancer

Trial Profile

A Phase 1B Dose-Escalation Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Patients With Stage 4 Non-Squamous Cell Lung Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Oct 2017

At a glance

  • Drugs Carotuximab (Primary) ; Bevacizumab; Carboplatin; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors TRACON Pharmaceuticals
  • Most Recent Events

    • 15 Oct 2017 According to a TRACON Pharmaceuticals media release, data was presented at the 18th World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer (IASLC).
    • 15 Oct 2017 Results presented in a TRACON Pharmaceuticals media release.
    • 14 Mar 2016 The company has initiated dosing in this trial and top-line data are expected in 2017, according to a Tracon Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top